Abbreviated Induction with Fludarabine/Cyclophosphamide/Dose-Dense Rituximab in Previously Untreated CLL (>65 Years)


Abbreviated Induction with Fludarabine/Cyclophosphamide/Dose-Dense Rituximab in Previously Untreated CLL (>65 Years)
Slides from a presentation at ASH 2012 and transcribed comments from a recent interview with Bruce D Cheson, MD (2/25/13)
Dartigeas C et al. Safety and efficacy of abbreviated induction with oral fludarabine (F) and cyclophosphamide (C) combined with dose-dense IV rituximab (R) in previously untreated patients with chronic lymphocytic leukemia (CLL) aged > 65 years: Results of a multicenter trial (LLC 2007 SA) on behalf of the French Goelams/Fcgcll-WM Intergroup. Proc ASH 2012;Abstract 434.

Dr Cheson is Professor of Medicine, Deputy Chief of the Division of Hematology-Oncology and Head of Hematology at the Georgetown University Hospital Lombardi Comprehensive Cancer Center in Washington, DC.